Rapamycin is the darling of the longevity world, but its biggest real-world human test just came back unimpressive. Among 4,885 kidney transplant patients on rapamycin and 6,589 who weren't, median survival age was 64.6 vs 64.3 years, a statistically similar result after adjustment. Over a median 11-year follow-up with 6,443 deaths, researchers saw no meaningful lifespan gain. But the study involved transplant patients on immunosuppressive regimens and was observational, so it can't settle whether low, intermittent dosing works in healthy people. Here's what it does and doesn't tell you.
This page is available in